COVA-493

N/A

Report date: 2026/03/19 16:53:35

Base Information

Drug NameCOVA-493

Drug Alias Namebispecific FynomAbs (Covagen)anti-CD3/anti-EGFR bispecific T-cell engager (Covagen)COVA-493COVA-494

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT lymphocytes stimulantsT cell surface glycoprotein CD3 modulatorsImmunostimulants +[4]

TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCovagen Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCovagen Ag

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A